Brand GLP-1 prices collapsed in 2025–2026, making the gray market’s price advantage nearly irrelevant. In many cases, legitimate medications are now cheaper than research peptides of unknown purity.
| Channel | Monthly Cost | Safety | Details |
|---|---|---|---|
| With insurance + savings card | $25/mo | FDA-Approved | Wegovy and Zepbound copay cards cover most commercially insured patients. Many pay $0. |
| Medicare (mid-2026) | ~$50/mo | FDA-Approved | Cardiovascular indication coverage. Negotiated pricing under Medicare Part D. |
| Oral Wegovy | $149/mo | FDA-Approved | Pill form, no injections. Launched January 2026. Cash price. |
| Hims/Ro telehealth (brand) | $199–349/mo | Licensed | FDA-approved Wegovy via Novo Nordisk partnership. Includes physician consult. |
| LillyDirect Zepbound vials | $299/mo | FDA-Approved | Direct from Eli Lilly. 2.5mg single-dose vials. No middlemen. |
| NovoCare Wegovy cash | $349/mo | FDA-Approved | All doses. Introductory pricing: $199/mo for first 2 months. |
| Gray-market research vial | $40–150/mo | Unregulated | 7–14% actual purity. Endotoxin detected in 100% of samples tested. No recourse if harmed. |
In 2023, the price ratio between brand semaglutide ($1,000+/mo) and gray-market research peptides (~$40/mo) was roughly 25:1. That gap justified the risk for many people. Today the ratio is approximately 3.5:1 ($349 vs $100) at cash prices — and with manufacturer savings cards, legitimate GLP-1s are often cheaper than gray-market alternatives of unknown composition. The economic argument for research peptides has fundamentally collapsed.
With savings cards, the legitimate option is often cheaper than the gray market. See current pricing from verified providers.
Find Care →We maintain a verified directory of FDA-approved GLP-1 telehealth providers, ranked by cost and transparency. Every provider prescribes brand medications through licensed physicians.
Find legitimate care